<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01576523</url>
  </required_header>
  <id_info>
    <org_study_id>CSL830_2001</org_study_id>
    <secondary_id>2011-005013-36</secondary_id>
    <nct_id>NCT01576523</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route</brief_title>
  <official_title>An Open-label, Cross-over, Dose-ranging Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of the Subcutaneous Administration of a Human Plasma-derived C1-esterase Inhibitor in Subjects With Hereditary Angioedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CSL Behring</source>
  <brief_summary>
    <textblock>
      The aim of the study is to assess what happens to C1-esterase inhibitor that is administered
      under the skin of subjects with hereditary angioedema. Three different dosing regimens of
      C1-esterase inhibitor will be assessed. Each subject will be assigned to receive 2 of the 3
      dosing regimens, each for 4 weeks. The activity and concentration of C1-esterase inhibitor in
      the blood will be measured during each 4-week period. The study will also examine how well
      C1-esterase inhibitor administered under the skin is tolerated by the subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modeled C1-esterase inhibitor functional activity trough level</measure>
    <time_frame>13 time points during each 4-week dose regimen</time_frame>
    <description>Mean trough C1-esterase inhibitor functional activity of the low, medium and high subcutaneous dose regimens, based on modeling and simulation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>C1-esterase inhibitor functional activity trough level</measure>
    <time_frame>2 time points during the last week of each 4-week dose regimen</time_frame>
    <description>Mean trough C1-esterase inhibitor functional activity of the low, medium and high subcutaneous dose regimens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C1-esterase inhibitor concentration trough level</measure>
    <time_frame>2 time points during the last week of each 4-week dose regimen</time_frame>
    <description>Mean trough C1-esterase inhibitor concentration of the low, medium and high subcutaneous dose regimens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C4 concentration trough level</measure>
    <time_frame>2 time points during the last week of each 4-week dose regimen</time_frame>
    <description>Mean trough C4 concentration of the low, medium and high subcutaneous dose regimens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C1-esterase inhibitor functional activity</measure>
    <time_frame>After four weeks of treatment with each dose regimen</time_frame>
    <description>Mean change from baseline of C1-esterase inhibitor functional activity of the low, medium and high subcutaneous dose regimens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C1-esterase inhibitor concentration</measure>
    <time_frame>After four weeks of treatment with each dose regimen</time_frame>
    <description>Mean change from baseline of C1-esterase inhibitor concentration of the low, medium and high subcutaneous dose regimens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C4 concentration</measure>
    <time_frame>After four weeks of treatment with each dose regimen</time_frame>
    <description>Mean change from baseline of C4 concentration of the low, medium and high subcutaneous dose regimens</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Hereditary Angioedema Types I and II</condition>
  <arm_group>
    <arm_group_label>Low, then medium, C1-esterase inhibitor dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium, then low, C1-esterase inhibitor dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium, then high, C1-esterase inhibitor dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low, then high, C1-esterase inhibitor dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High, then low, C1-esterase inhibitor dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High, then medium, C1-esterase inhibitor dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>C1-esterase inhibitor - single intravenous dose</intervention_name>
    <description>A single intravenous dose of C1-esterase inhibitor (Berinert) at 20 units per kg body weight will be administered to all subjects prior to receiving the first dose of subcutaneous C1-esterase inhibitor.</description>
    <arm_group_label>Low, then medium, C1-esterase inhibitor dose</arm_group_label>
    <arm_group_label>Low, then high, C1-esterase inhibitor dose</arm_group_label>
    <arm_group_label>Medium, then low, C1-esterase inhibitor dose</arm_group_label>
    <arm_group_label>Medium, then high, C1-esterase inhibitor dose</arm_group_label>
    <arm_group_label>High, then low, C1-esterase inhibitor dose</arm_group_label>
    <arm_group_label>High, then medium, C1-esterase inhibitor dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>C1-esterase inhibitor - subcutaneous low dose</intervention_name>
    <description>A low dose of C1-esterase inhibitor will be administered subcutaneously twice a week for four weeks.</description>
    <arm_group_label>Low, then medium, C1-esterase inhibitor dose</arm_group_label>
    <arm_group_label>Medium, then low, C1-esterase inhibitor dose</arm_group_label>
    <arm_group_label>Low, then high, C1-esterase inhibitor dose</arm_group_label>
    <arm_group_label>High, then low, C1-esterase inhibitor dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>C1-esterase inhibitor - subcutaneous medium dose</intervention_name>
    <description>A medium dose of C1-esterase inhibitor will be administered subcutaneously twice a week for four weeks.</description>
    <arm_group_label>Low, then medium, C1-esterase inhibitor dose</arm_group_label>
    <arm_group_label>Medium, then low, C1-esterase inhibitor dose</arm_group_label>
    <arm_group_label>Medium, then high, C1-esterase inhibitor dose</arm_group_label>
    <arm_group_label>High, then medium, C1-esterase inhibitor dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>C1-esterase inhibitor - subcutaneous high dose</intervention_name>
    <description>A high dose of C1-esterase inhibitor will administered subcutaneously twice a week for four weeks.</description>
    <arm_group_label>Medium, then high, C1-esterase inhibitor dose</arm_group_label>
    <arm_group_label>Low, then high, C1-esterase inhibitor dose</arm_group_label>
    <arm_group_label>High, then low, C1-esterase inhibitor dose</arm_group_label>
    <arm_group_label>High, then medium, C1-esterase inhibitor dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females aged 18 years or older.

          -  Laboratory-confirmed hereditary angioedema type I or II.

          -  Less than two hereditary angioedema attacks per month in the last three months.

          -  Body weight of 50.0 kg to 110.0 kg.

        Exclusion Criteria:

          -  Receiving prophylactic C1-esterase inhibitor therapy.

          -  Received C1-esterase inhibitor, ecallantide, icatibant or any blood products for the
             prevention or treatment of hereditary angioedema within 7 days before the screening
             visit.

          -  Intends to use recombinant C1-esterase inhibitor or fresh frozen plasma for the acute
             treatment of hereditary angioedema during the study.

          -  Received androgen therapy (e.g., danazol, oxandrolone, stanozolol, testosterone)
             within 30 days before the screening visit.

          -  Female subjects who started taking or changed dose of any hormonal contraceptive
             regimen or hormone replacement therapy (i.e., estrogen/progesterone-containing
             products) within 3 months prior to the screening visit.

          -  Known or suspected hypersensitivity to the study product, or to any excipients of the
             study product.

          -  Pregnancy or lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Program Director</last_name>
    <role>Study Director</role>
    <affiliation>CSL Behring</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>19108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Zuraw BL, Cicardi M, Longhurst HJ, Bernstein JA, Li HH, Magerl M, Martinez-Saguer I, Rehman SM, Staubach P, Feuersenger H, Parasrampuria R, Sidhu J, Edelman J, Craig T. Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate. Allergy. 2015 Oct;70(10):1319-28. doi: 10.1111/all.12658. Epub 2015 Aug 11.</citation>
    <PMID>26016741</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2012</study_first_submitted>
  <study_first_submitted_qc>April 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2012</study_first_posted>
  <disposition_first_submitted>January 28, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>January 28, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 28, 2014</disposition_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
    <mesh_term>Hereditary Angioedema Types I and II</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Complement C1s</mesh_term>
    <mesh_term>Complement C1 Inhibitor Protein</mesh_term>
    <mesh_term>Complement C1 Inactivator Proteins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

